Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06
Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK...
Deals
Haisco Pharmaceutical Announces Public Offering for Clinical Studies
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) is set to make another public offering...
Ji Xing Pharmaceuticals Acquires Global Rights to PhaseBio’s PB6440
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...
Zhejiang Gongdong to Acquire Trademark Plastics for Overseas Expansion
China-based Zhejiang Gongdong Medical Technology Co., Ltd is set to acquire core assets of US...
Shanghai Weimu Medical Raises Pre-Series A+ Funding for Clinical Development
China-based high-end interventional device maker Shanghai Weimu Medical Technology Co., Ltd has reportedly raised “tens...
MicroPort Endovascular Plans RMB 2.55 Billion Private Placement
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) plans to raise up to RMB...
Virpax Pharmaceuticals Seeks China Licensing Partner for Non-Opioid Pain Drug Envelta
US-based Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) has announced the engagement of advisors to help search...
NeuShen Therapeutics Partners with UMass Chan for ALS Gene Therapy Development
Sino-US biotech firm NeuShen Therapeutics Inc., focused on central nervous system (CNS) disorders, has announced...
F-Star Therapeutics and Sino Biopharmaceutical Seek CFIUS Approval with Extended Deadline
The acquisition of UK-based biologics firm F-Star Therapeutics (NASDAQ: FSTX) by China’s Sino Biopharmaceutical (HKG:...
Junshi Biosciences Partners with Huahai for Production of COVID-19 Drug VV116
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a production and supply agreement between...
R&B Bio Raises RMB 200 Million in Series A+ Round to Advance Gene Therapy Pipeline
Chengdu-based gene therapy firm R&B Biotech has reportedly secured over RMB 200 million (USD 29.64...
Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development
South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals...
Zhifei Renews Vaccine Supply Agreement with Merck Sharp & Dohme
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the renewal of a supply,...
Enkang Pharma Secures Series B Funding for DRIPs-Targeted Cancer Therapy
Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd, a developer of DNA replication-initiation proteins (DRIPs)-targeted drugs, has...
CARsgen and Roche Partner on Clinical Study for Gastric Cancer Treatment
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a clinical cooperation...
Tigermed Completes Acquisition of Croatia-Based CRO Marti Farm
China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the completion of...
RemeGen and Allist Partner to Assess ADC and EGFR Inhibitor Combination in NSCLC
China-based RemeGen Ltd (HKG: 9995) and Allist Pharmaceuticals Inc. (SHA: 688578) have announced a clinical...
Akeso Receives First $300M Installment from Summit for Bispecific Antibody Ivonescimab
Akeso Inc. (HKG: 9926) has announced receiving the first installment of USD 300 million as...
HutchMed Signs Licensing Deal with Takeda for Global Fruquintinib Development
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced a licensing deal with Japanese...